Form 8-K - Current report:
SEC Accession No. 0001193125-25-274596
Filing Date
2025-11-10
Accepted
2025-11-10 17:24:38
Documents
15
Period of Report
2025-11-08
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d12611d8k.htm   iXBRL 8-K 44881
2 EX-99.1 d12611dex991.htm EX-99.1 23905
3 EX-99.2 d12611dex992.htm EX-99.2 24242
7 GRAPHIC g12611g1111003715793.jpg GRAPHIC 6795
  Complete submission text file 0001193125-25-274596.txt   238874

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ntla-20251108.xsd EX-101.SCH 2846
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20251108_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20251108_pre.xml EX-101.PRE 11258
17 EXTRACTED XBRL INSTANCE DOCUMENT d12611d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 251467468
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)